Polimanti, R
Kaufman, J
Zhao, H
Kranzler, H R
Ursano, R J
Kessler, R C
Gelernter, J
Stein, M B
Article History
Received: 11 August 2016
Revised: 9 January 2017
Accepted: 17 January 2017
First Online: 7 March 2017
Competing interests
: In the past 3 years, Dr Stein has been a consultant for Actelion Pharmaceuticals, Healthcare Management Technologies, Janssen, Neurocrine, Pfizer, Resilience Therapeutics, Tonix Pharmaceuticals and Oxeia Biopharmaceuticals. Dr Kaufman has provided consultation to Pfizer and Merck Pharmaceutical Company to train investigators to assess bipolar disorder in youth. Dr Kranzler has been an advisory board member, consultant or CME speaker for Indivior, Lundbeck and Otsuka. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which is supported by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Pfizer and XenoPort. In the past 3 years, Dr Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research. The remaining authors declare no conflict of interest.